Over the 6-month follow-up, patients treated with GLP-1 RA showed the greatest mean improvements in steatosis (CAP −50 dBm) and fibrosis (FibroScan −1.0 kPa), a finding also noted for the SGLT2i subgroup, but with smaller magnitudes. The gene discussed is GLP1R; the disease is steatosis.